VistaGen Therapeutics Valuation
| VTGN Stock | USD 2.73 0.15 5.81% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. VistaGen Therapeutics has a current Real Value of $5.08 per share. The regular price of the company is $2.73. Our model measures the value of VistaGen Therapeutics from inspecting the company fundamentals such as Return On Equity of -0.62, shares owned by insiders of 0.24 %, and Current Valuation of (23.95 M) as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting VistaGen Therapeutics' valuation include:
Price Book 0.7726 | Enterprise Value -23.9 M | Enterprise Value Ebitda (0.19) | Price Sales 81.9767 | Enterprise Value Revenue 8.0488 |
Undervalued
Today
Please note that VistaGen Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of VistaGen Therapeutics is based on 3 months time horizon. Increasing VistaGen Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since VistaGen Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of VistaGen Stock. However, VistaGen Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.73 | Real 5.08 | Target 12.0 | Hype 2.71 |
The intrinsic value of VistaGen Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence VistaGen Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of VistaGen Therapeutics helps investors to forecast how VistaGen stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VistaGen Therapeutics more accurately as focusing exclusively on VistaGen Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use VistaGen Therapeutics' intrinsic value based on its ongoing forecasts of VistaGen Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against VistaGen Therapeutics' closest peers.
VistaGen Therapeutics Cash |
|
VistaGen Valuation Trend
Knowing VistaGen Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both VistaGen Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
VistaGen Therapeutics Total Value Analysis
VistaGen Therapeutics is at this time forecasted to have valuation of (23.95 M) with market capitalization of 71.84 M, debt of 2.12 M, and cash on hands of 51.99 M. The negative valuation of VistaGen Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the VistaGen Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(23.95 M) | 71.84 M | 2.12 M | 51.99 M |
VistaGen Therapeutics Investor Information
About 54.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.77. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. VistaGen Therapeutics recorded a loss per share of 0.74. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 7th of June 2023. Based on the key indicators related to VistaGen Therapeutics' liquidity, profitability, solvency, and operating efficiency, VistaGen Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.VistaGen Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. VistaGen Therapeutics has an asset utilization ratio of 0.86 percent. This suggests that the Company is making $0.008605 for each dollar of assets. An increasing asset utilization means that VistaGen Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.VistaGen Therapeutics Ownership Allocation
VistaGen Therapeutics shows a total of 27.84 Million outstanding shares. Over half of VistaGen Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.VistaGen Therapeutics Profitability Analysis
The company reported the previous year's revenue of 1.06 M. Net Loss for the year was (29.36 M) with loss before overhead, payroll, taxes, and interest of (227.3 K).About VistaGen Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of VistaGen Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of VistaGen Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing VistaGen Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of VistaGen Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of VistaGen Therapeutics. We calculate exposure to VistaGen Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of VistaGen Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 496 K | 253.2 K | |
| Pretax Profit Margin | (27.59) | (26.21) | |
| Operating Profit Margin | (31.03) | (29.48) | |
| Net Loss | (27.60) | (26.22) | |
| Gross Profit Margin | 0.47 | 0.49 |
VistaGen Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 19.4 M |
VistaGen Therapeutics Current Valuation Indicators
VistaGen Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final VistaGen Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as VistaGen Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use VistaGen Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes VistaGen Therapeutics' worth.When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.